Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 1305-1313, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holten-Andersen, M. N.
Right arrow Articles by Piironen, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holten-Andersen, M. N.
Right arrow Articles by Piironen, T.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:1305-1313.)
© 2002 American Association for Clinical Chemistry, Inc.

Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases 1 in Plasma by Immunoassay

Mads N. Holten-Andersen1a, Ib Jarle Christensen1, Hans Jørgen Nielsen2, Hans Lilja3, Gillian Murphy4, Vibeke Jensen1, Nils Brünner1 and Timo Piironen1

1 The Finsen Laboratory, Rigshopitalet, Strandboulevarden 49, 2100 Copenhagen, Denmark.

2 Department of Surgical Gastroenterology, Hvidovre University Hospital, 2650 Hvidovre, Denmark.

3 Department of Clinical Chemistry, Malmö University Hospital, 20502 Malmö, Sweden.

4 School of Biological Sciences, University of East Anglia Norwich, NR4 7TJ, United Kingdom.

aAuthor for correspondence. Fax 45-35-25-11-17; e-mail mads{at}finsenlab.dk.

Background: We previously found differences in total concentrations of tissue inhibitor of metalloproteinases 1 (TIMP-1) in plasma from donors and cancer patients. Because TIMP-1 can exist in more than one molecular form, a new immunoassay to specifically detect free TIMP-1 was developed and concentrations were determined in plasma from healthy donors and colorectal cancer (CRC) patients.

Methods: We established and validated an immunoassay for the specific measurement of free TIMP-1 that uses a polyclonal anti-TIMP-1 antibody for capture and a monoclonal anti-TIMP-1 antibody that binds only free TIMP-1 for detection of antigen. Plasma samples from healthy donors and CRC patients were assayed for free TIMP-1. Total TIMP-1 was measured by our previously published assay.

Results: The mean (SD) concentrations of free TIMP-1 were similar in citrate [55.5 (11.5) µg/L] and EDTA plasma [58.9 (13.3) µg/L] from 76 donors (r2 = 0.82). In 154 donors, the ratio of free TIMP-1 [mean (SD), 64.5 (18.0) µg/L] to total TIMP-1 [83.8 (19.8) µg/L] in EDTA plasma was 0.77. Plasma concentrations of free and total TIMP-1 correlated significantly to age (free, r2 = 0.19; total, r2 = 0.27; P <0.0001), increasing 50% over an age span of 45 years. Free and total TIMP-1 were significantly increased in CRC patients (P <0.0001), whereas the ratio of free to total TIMP-1 (mean, 0.58) was significantly lower than in donors.

Conclusions: Most of the TIMP-1 in donor plasma is present in its free form, and free TIMP-1 increases with age. Free and total TIMP-1 are increased in CRC patient plasma, but the ratio of free to total TIMP-1 is significantly lower in these patients than in donors.




The following articles in journals at HighWire Press have cited this article:


Home page
Mol. Cell. ProteomicsHome page
S. O. Wurtz, I. J. Christensen, A.-S. Schrohl, H. Mouridsen, U. Lademann, V. Jensen, and N. Brunner
Measurement of the Uncomplexed Fraction of Tissue Inhibitor of Metalloproteinases-1 in the Prognostic Evaluation of Primary Breast Cancer Patients
Mol. Cell. Proteomics, April 1, 2005; 4(4): 483 - 491.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. Chromek, K. Tullus, J. Lundahl, and A. Brauner
Tissue Inhibitor of Metalloproteinase 1 Activates Normal Human Granulocytes, Protects Them from Apoptosis, and Blocks Their Transmigration during Inflammation
Infect. Immun., January 1, 2004; 72(1): 82 - 88.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.